Literature DB >> 15957968

Review of current treatment practices for carcinoma of the head and neck.

Bijal J Modi1, Brian Knab, Lawrence E Feldman, Arno J Mundt, Mike Yao, Kristen B Pytynia, Joel Epstein.   

Abstract

The past two decades have witnessed a paradigm shift in the treatment of squamous cell carcinoma of the head and neck. Innovation in chemotherapy, radiotherapy and surgery has led to the assimilation of these modalities into our treatment algorithms. This modern multipart treatment plan has led to improved survival; however, this has come at the cost of increased toxicity. New and future therapies will be more tumour specific and, ideally, less toxic. Current research centres on these tumour-specific therapies with the anticipation of improved survival with decreased toxicity. This article will review the standard of care, recent advances and unfulfilled needs in the treatment of squamous cell carcinoma of the head and neck.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15957968     DOI: 10.1517/14656566.6.7.1143

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

1.  A prospective study to assess in vivo optical coherence tomography imaging for early detection of chemotherapy-induced oral mucositis.

Authors:  Alden Calantog; Lucy Hallajian; Tasneem Nabelsi; Stephanie Mansour; Anh Le; Joel Epstein; Petra Wilder-Smith
Journal:  Lasers Surg Med       Date:  2013-01-15       Impact factor: 4.025

2.  Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy.

Authors:  Joel B Epstein; Diana J Wilkie; Dena J Fischer; Young-Ok Kim; Dana Villines
Journal:  Head Neck Oncol       Date:  2009-07-14

3.  A survey of National Cancer Institute-designated comprehensive cancer centers' oral health supportive care practices and resources in the USA.

Authors:  Joel B Epstein; Ira R Parker; Matthew S Epstein; Anurag Gupta; Susan Kutis; Daniela M Witkowski
Journal:  Support Care Cancer       Date:  2007-01-05       Impact factor: 3.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.